KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Buys 14,562 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par purchased 14,562 shares of the stock in a transaction on Monday, February 3rd. The stock was acquired at an average cost of $9.22 per share, for a total transaction of $134,261.64. Following the acquisition, the insider now directly owns 5,012,796 shares in the company, valued at approximately $46,217,979.12. This trade represents a 0.29 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average price of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Trading Up 5.7 %

KalVista Pharmaceuticals stock opened at $9.75 on Wednesday. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $16.88. The company has a market cap of $481.85 million, a PE ratio of -2.68 and a beta of 0.85. The company’s 50-day moving average is $8.81 and its two-hundred day moving average is $10.77.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. Research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of KALV. The Manufacturers Life Insurance Company increased its stake in shares of KalVista Pharmaceuticals by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after acquiring an additional 3,314 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $153,000. China Universal Asset Management Co. Ltd. increased its stake in KalVista Pharmaceuticals by 67.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after purchasing an additional 3,328 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its stake in KalVista Pharmaceuticals by 23.0% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after purchasing an additional 121,615 shares in the last quarter. Finally, Emerald Advisers LLC increased its stake in KalVista Pharmaceuticals by 29.8% during the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after purchasing an additional 192,091 shares in the last quarter.

Analyst Upgrades and Downgrades

KALV has been the topic of several recent analyst reports. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. TD Cowen started coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Finally, JMP Securities started coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $23.80.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).